Revenue exceeds previous forecast

PO Box 1387, Gisborne 4040, Aotearoa New Zealand | 0800 RUABIO | www.ruabio.com





FOR PUBLIC RELEASE

NZX Limited
Wellington

28 January 2025

Rua Bioscience exceeds previous revenue forecast

Rua Bioscience has achieved unaudited revenue of $693,829 for the six months ending
December 31, 2024. This result significantly exceeds the company's forecast for the
period, reflecting robust growth in our key markets of Germany, Australia, and New
Zealand.

During our recent capital raise process in November 2024, Rua had forecast sales of
$600,000 for the six-month period. The higher-than-expected demand, particularly in
New Zealand and Germany, is the primary driver of the increase.



Both Germany and New Zealand ended the year with exceptionally strong sales of our
new dried flower products. Germany in particular, which is Europe’s largest medicinal
cannabis market, continues to see rising demand driven by changes to regulations in
April last year.

23
45
223
471
Q3 FY 24
Jan - Mar
Q4 FY24
Apr - Jun
Q1 FY25
Jul - Sep
Q2 FY25
Oct - Dec
Quarterly sales revenue
(Unaudited, NZ$ 000)
MARKET UPDATE

PO Box 1387, Gisborne 4040, Aotearoa New Zealand | 0800 RUABIO | www.ruabio.com
CEO Paul Naske stated, "This milestone demonstrates the effectiveness of our export-led
strategy and provides evidence that we are delivering on our plans."

The company's priorities for the remainder of FY25 include working with suppliers to
increase volumes to meet demand in our key markets and expanding our product
portfolio.

With a clear roadmap for achieving sustainable revenue and profit, Rua Bioscience is
fulfilling its vision of changing lives in our community.


ENDS  
 

The person who authorised this announcement:

Paul Naske
Chief Executive Officer
paul.naske@ruabio.com
+64 21 445154